Meeting
2023 ASCO Annual Meeting
15-month safety and efficacy data after intraperitoneal treatment with 224Radium-labelled microparticles after CRS-HIPEC for peritoneal metastasis from colorectal cancer.
Authors
Stein G Larsen
Norwegian Radium Hospital, Oslo, Norway
Stein G Larsen , Wilhelm Graf , Olaf Sørensen , Anthony Burton Mariathasan , Milan Spasojevic , Lana Ghanipour , Peter Cashin , Øyvind Bruland
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT03732781
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3518)
DOI
10.1200/JCO.2023.41.16_suppl.3518
Abstract #
3518
Poster Bd #
218
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Efficacy and safety of camrelizumab in combination with radiation and chemotherapy for recurrent or metastatic cervical cancer.
First Author: Zhongjie Chen
Poster
2023 ASCO Annual Meeting
Phase I/II trial of durvalumab plus tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma: Final results.
First Author: Houda Bahig
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Cytoreductive surgery and HIPEC in colorectal cancer peritoneal metastases (CRPM): Real-world outcomes in systemic anticancer treatment–naïve patients.
First Author: Nadina Tinsley
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Short-term safety of adjuvant nivolumab therapy after neoadjuvant docetaxel plus cisplatin and 5-FU therapy for locally advanced esophageal squamous cell carcinoma.
First Author: Toshiharu Hirose